Individuals with chronic obstructive pulmonary disease (COPD) have long been identified to have an elevated serum level of angiotensin‐converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The newest discoveries by Higham et al. (1) were the increased ACE2 expression in the bronchial epithelium of overweight COPD patients compared to their non‐overweight counterparts.
|Number of pages||1|
|Early online date||21 Jul 2020|
|Publication status||Published - 1 Nov 2020|
FingerprintDive into the research topics of 'The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19'. Together they form a unique fingerprint.
Study says inhalers OK to use amid COVID-19 concerns
Hamid Merchant, Syed Shahzad Hasan, Toby Capstick, Syed Tabish Razi Zaidi & Chia Siang Kow
7/07/20 → 13/07/20
13 items of Media coverage